Abstract

New Coronavirus Disease (COVID-19) is a viral pathology which was first described in Wuhan City of China in late December, as a result of investigations made in a group of patients with respiratory tract symptoms (fever, cough, dyspnea). In 11th February 2020, International Committee on Taxonomy of Viruses (ICTV) declared the name of this new virus as “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)”. This name was chosen due to the relationship of this virus with the coronavirus responsible for 2003 SARS pandemic. Despite this relationship, these two viruses are different [1]. This virus has appeared as a zoonotic virus which mutated to allow human pathogenicity or adapted in a different way [1]. In 30th January 2020, WHO declared COVID-19 as an international public health emergency and a pandemic in 11th March 2020 [1]. An effective treatment is urgently required to treat symptomatic patients, limit the spread of virus in community and decrease viral transport. In this review, the effectiveness of the drugs used in the treatment of Covid-19 and relevance with endocrinologic diseases have been evaluated.

Keywords: Covid-19; Endocrinology; Treatment

References

1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. “The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020”. China CDC Weekly (2020).
2. Deng SQ and Peng HJ. “Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China”. Journal of Clinical Medicine 2 (2020): 575.
3. Orioli L., et al. “COVID-19 in diabetic patients: Related risks and specifics of management”. Annales d'Endocrinologie 2-3 (2020): 101-109.
4. Puig-Domingo M., et al. “COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology”. Endocrine1 (2020): 2-5.
5. Hydroxychloroquine: Drug information. UpTo Date.
6. Favipiravir (United States: Not commercially available; refer to Prescribing and Access Restrictions): Drug information. UpTo Date.
7. Remdesivir (United States: Investigational agent; refer to Prescribing and Access Restrictions): Drug information. UpTo Date.
8. Tocilizumab: Drug information. UpTo Date.
9. Anakinra: Drug information. UpTo Date.
10. Coronavirus disease 2019 (COVID-19): Hypercoagulability. UpTo Date.
11. Coronavirus disease 2019 (COVID-19): Critical care and airway management issues.
12. “Investigational COVID-19 Convalescent Plasma Emergency INDs”. erişim (2020). Recommendations for Investigational COVID-19 Convalescent Plasma.
13. Coronavirus disease 2019 (COVID-19): Convalescent plasma and hyperimmune globulin. UpTo Date.